3-298 (median: 18), 2-65 ng/ml (median: 7). The 5 years DSF of UP group or non-UP group were 18.8%, 27.3% (p=0.645), and the 5 OS were 48.1%, 84.2% (p=0.04). Conclusion: In RFA as first therapy for SN-or SNIM-type HCC (< 30 mm, single nodule), it was suggested :that some increasing of the level of AFP before operation had relation to OS.
Aim: To evaluate clinico-pathological profile, perioperative and short term outcomes of patients undergoing liver resections for oncological indications. Materials and methods: Analysis of patients undergoing liver resections from June 2010 to October 2017. Results: Five hundred and one patients were operated during the study period. Median age was 55 years (M: F 1.66:1). Forty-three patients (8.6%) had benign disease and 458 (91.4%) patients had malignant disease. Most common primary malignant were hepatocellular carcinoma (HCC) 161 (32.1%), intra hepatic cholangiocarcinomas (IHCC) 39 (7.8%) and perihilar cholangiocarcinomas (pHCCA) 30 (6.0%). Most commonly resected secondary neoplasm was metastases from colorectal cancer (MCRC) 123 (24.6%). Major hepatic resections (!3 segments) were performed in 217 patients. Overall morbidity was 22.7% (n=114) and mortality was 3.4% (n=17).
Chronic HBV infection was commonest etiology for HCC (n=36, 51.4%). Seventy (43.5%) with HCC were cirrhotic. TACE was performed as bridge to surgery in 48 patients (29.8%). R0 resection was feasible in 148 (91.9%).
R0 resection was feasible in 65.21% (n=45) of patients with cholangiocarcinoma.
Fifty-seven (46.34%) of 123 MCRC patients operated had synchronous metastases. Simultaneous resection was performed in 26 where a major hepatectomy with left colonic or rectal resection performed in 5 cases. R0 resection rate was 90.2% (n=111). Conclusion: Outside transplant setting, this is the largest series of liver resections from India. Resection for liver tumors still plays a major role and can be performed with acceptable morbidity and mortality in resource constraint population EP01B-057 TRANSARTERIAL CHEMOEMBOLIZATION FOR INOPERABLE HEPATOCELLULAR CARCINOMA e A SINGLE CENTER 6-YEAR EXPERIENCE E. Malcevs 1 , A. Ozolins 1,2 , A. Veiss 1 , J. Vilmanis 1,2 , J. Savlovskis 1 and J. Gardovskis 1,2 1 Pauls Stradins Clinical University Hospital, and 2 Rigas Stradins University, Latvia Introduction: Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide in terms of number of cases and it is the third most common cause of death from cancer. Targeted transarterial chemoembolization (TACE) therapy is currently the standard treatment for advanced HCC in selected cases. Methods: A retrospective study was conducted with advanced HCC patients who underwent TACE in the time period from 2011 until 2016. Manipulation efficiency and survival outcomes were analyzed. Biopsy and CT imaging diagnosed a total of 37 patients with advanced HCC. Patients were evaluated according to Barcelona Clinic Liver Cancer (BCLC) staging by a multidisciplinary team and advised TACE as the treatment option. Results: Mean patient age was 64.21 AE 11.05 years. The female-to-male ratio was 1,86. Tumor was localized in HPB 2018, 20 (S2), S333eS504
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